Shanghai Huiqi Biomedical Technology

Shanghai Huiqi Biomedical Technology is a Shanghai-based biotechnology company dedicated to the discovery and development of innovative small molecule drugs for the treatment of cancer and other life-threatening diseases. Founded in 2021 by a team of experienced pharmaceutical scientists, the company focuses on targeting key signaling pathways and challenging biological targets such as ubiquitin-specific proteases. Huiqi Bio utilizes a structure-based drug design approach to develop highly selective and potent candidates, with its lead program, HQ-001, currently in Phase 1 clinical trials. The company has successfully raised significant venture capital from top-tier investors like Matrix Partners China and Qiming Venture Partners to accelerate its pipeline of first-in-class therapeutics.